Market Place
Sourcing Support
MindBio Reports Sustained Response In Microdosing Depression Trials
19 Aug 2024 //
ACCESSWIRE
MindBio Therapeutics Appoints Haywood Securities As Advisor
01 Aug 2024 //
ACCESSWIRE
Mindbio Therapeutics CEO Issues Letter To Shareholders
08 Jul 2024 //
ACCESSWIRE
MindBio Reports Sustained Antidepressant Effect Of MB22001 In Depression Trial
20 Jun 2024 //
ACCESSWIRE
MindBio Therapeutics Reports Phase 2A Depression Trial Results
12 Jun 2024 //
ACCESSWIRE
Enveric Biosciences to out-license psilocin prodrug to MindBio
15 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Enveric Signs $66.5M Term Sheet For Psilocin Mental Health Candidate
14 May 2024 //
BUSINESSWIRE
MindBio Presents Women`s Health Data, To Release Depression Data
02 May 2024 //
ACCESSWIRE
MindBio Explores Senior Listing With Phase 2B Trials Underway
01 May 2024 //
ACCESSWIRE
MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials
30 Apr 2024 //
ACCESSWIRE
MindBio Sleep Research In Nature Translational Psychiatry
23 Apr 2024 //
ACCESSWIRE
Lender Requests to Convert Loan to MindBio Shares
16 Apr 2024 //
ACCESSWIRE
MindBio Receives Approval to Conduct Phase 2B Trial Microdosing Mb22001
04 Mar 2024 //
ACCESSWIRE
MindBio Announces Depression Data from Ph 2a Take-Home Microdosing Trial
26 Feb 2024 //
ACCESSWIRE
MindBio Completes World First Take Home Phase 2a Microdosing Depression Trial
14 Feb 2024 //
ACCESSWIRE
MindBio Nears Completion of Landmark Phase 2a LSD Microdosing (MB22001) Trial
30 Jan 2024 //
ACCESSWIRE
MindBio CEO Provides End of Year Video Update on Phase 2 Clinical Trials
20 Dec 2023 //
ACCESSWIRE
MindBio Therapeutics Team Members Honoured with Industry Leading Awards
21 Nov 2023 //
ACCESSWIRE
MindBio CEO Presents World First Phase 2B Take-Home Microdosing Trial
31 Oct 2023 //
ACCESSWIRE
MindBio Begins Dosing MB22001 in World First Phase 2B Microdosing Trial
28 Oct 2023 //
ACCESSWIRE
Mindbio Therapeutics Nominated for Company of the Year in Industry Awards
26 Oct 2023 //
ACCESSWIRE
MindBio CEO Provides Video Update on Phase 2a Depression Trial Using MB22001
24 Oct 2023 //
ACCESSWIRE
MindBio Therapeutics Announces Major Genetic Discovery in Microdosing Research
05 Sep 2023 //
ACCESSWIRE
Begins Dosing Mb22001 in PII Trial in World First Take-Home Microdosing Study
24 Aug 2023 //
ACCESSWIRE
Mindbio Therapeutics First Batch of MB22001 has Been Manufactured
18 Aug 2023 //
ACCESSWIRE
MindBio Begins Recruitment of Participants for World First LSD-Microdosing Trial
25 Jul 2023 //
ACCESSWIRE
MindBio Therapeutics World First Phase 2 Take-Home LSD-Microdosing Trial
19 Jul 2023 //
ACCESSWIRE
MindBio Microdosing Trial Reveals Positive Effects on Quality Of Sleep
14 Jun 2023 //
ACCESSWIRE
MindBio Co-Founders Appear in Leading Australian Financial News Publication
09 Jun 2023 //
ACCESSWIRE
MindBio Therapeutics CEO To Present at Emerging Equities Life Sciences VIP Event
06 Jun 2023 //
ACCESSWIRE
MindBio Approval for Landmark First Phase 2 Trial of Take-Home LSD-Microdosing
23 May 2023 //
ACCESSWIRE
MindBio Therapeutics CEO Issues Letter to Shareholders Discussing
16 May 2023 //
ACCESSWIRE
MindBio Reveals Scientific Paper in World-First Take-Home, LSD Trial in 80
09 May 2023 //
ACCESSWIRE
